169 related articles for article (PubMed ID: 7475823)
1. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation.
Gjertsen MK; Bakka A; Breivik J; Saeterdal I; Solheim BG; Søreide O; Thorsby E; Gaudernack G
Lancet; 1995 Nov; 346(8987):1399-400. PubMed ID: 7475823
[TBL] [Abstract][Full Text] [Related]
2. Mutated Ras peptides as vaccines in immunotherapy of cancer.
Gjertsen MK; Gaudernack G
Vox Sang; 1998; 74 Suppl 2():489-95. PubMed ID: 9704487
[TBL] [Abstract][Full Text] [Related]
3. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
[TBL] [Abstract][Full Text] [Related]
4. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.
Gjertsen MK; Buanes T; Rosseland AR; Bakka A; Gladhaug I; Søreide O; Eriksen JA; Møller M; Baksaas I; Lothe RA; Saeterdal I; Gaudernack G
Int J Cancer; 2001 May; 92(3):441-50. PubMed ID: 11291084
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study.
Gjertsen MK; Bakka A; Breivik J; Saeterdal I; Gedde-Dahl T; Stokke KT; Sølheim BG; Egge TS; Søreide O; Thorsby E; Gaudernack G
Int J Cancer; 1996 Feb; 65(4):450-3. PubMed ID: 8621226
[TBL] [Abstract][Full Text] [Related]
6. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
[TBL] [Abstract][Full Text] [Related]
7. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp).
Fossum B; Gedde-Dahl T; Breivik J; Eriksen JA; Spurkland A; Thorsby E; Gaudernack G
Int J Cancer; 1994 Jan; 56(1):40-5. PubMed ID: 7903287
[TBL] [Abstract][Full Text] [Related]
8. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
9. Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers.
Shono Y; Tanimura H; Iwahashi M; Tsunoda T; Tani M; Tanaka H; Matsuda K; Yamaue H
Br J Cancer; 2003 Feb; 88(4):530-6. PubMed ID: 12592366
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras.
Wedén S; Klemp M; Gladhaug IP; Møller M; Eriksen JA; Gaudernack G; Buanes T
Int J Cancer; 2011 Mar; 128(5):1120-8. PubMed ID: 20473937
[TBL] [Abstract][Full Text] [Related]
11. Induction of CTLs by DCs pulsed with K-ras mutant peptide on the surface of nanoparticles in the treatment of pancreatic cancer.
Tan G; Wang Z; Zhang X; Cai Z; Zhang J
Oncol Rep; 2011 Jul; 26(1):215-21. PubMed ID: 21573499
[TBL] [Abstract][Full Text] [Related]
12. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
[TBL] [Abstract][Full Text] [Related]
13. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
Kubuschok B; Neumann F; Breit R; Sester M; Schormann C; Wagner C; Sester U; Hartmann F; Wagner M; Remberger K; Schilling M; Pfreundschuh M
Clin Cancer Res; 2006 Feb; 12(4):1365-72. PubMed ID: 16489095
[TBL] [Abstract][Full Text] [Related]
14. Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.
Kubuschok B; Pfreundschuh M; Breit R; Hartmann F; Sester M; Gärtner B; König J; Murawski N; Held G; Zwick C; Neumann F
Hum Gene Ther; 2012 Dec; 23(12):1224-36. PubMed ID: 22966960
[TBL] [Abstract][Full Text] [Related]
15. CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients.
Qin H; Chen W; Takahashi M; Disis ML; Byrd DR; McCahill L; Bertram KA; Fenton RG; Peace DJ; Cheever MA
Cancer Res; 1995 Jul; 55(14):2984-7. PubMed ID: 7606715
[TBL] [Abstract][Full Text] [Related]
16. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.
Khleif SN; Abrams SI; Hamilton JM; Bergmann-Leitner E; Chen A; Bastian A; Bernstein S; Chung Y; Allegra CJ; Schlom J
J Immunother; 1999 Mar; 22(2):155-65. PubMed ID: 10093040
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic cancer, treatment options, and GI-4000.
Hartley ML; Bade NA; Prins PA; Ampie L; Marshall JL
Hum Vaccin Immunother; 2014; 10(11):3347-53. PubMed ID: 25585100
[TBL] [Abstract][Full Text] [Related]
18. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
19. Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model.
Kubuschok B; Schmits R; Hartmann F; Cochlovius C; Breit R; König J; Pistorius G; Schilling M; Renner C; Pfreundschuh M
Hum Gene Ther; 2002 May; 13(7):815-27. PubMed ID: 11975848
[TBL] [Abstract][Full Text] [Related]
20. [Anti-pancreatic cancer immune response induced by K-ras mutated peptide].
He Y; Yang B; Ruan CG
Ai Zheng; 2005 May; 24(5):559-62. PubMed ID: 15890097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
